ACOG

Alpha Cognition's stock has been influenced by several events over the past six months. The company announced an upsized public offering and Nasdaq listing in November 2024, providing capital for commercialization and development. It voluntarily delisted from the CSE in December 2024. Patent approvals were received for ALPHA-1062 and ZUNVEYL. Financial results included Q3 2025 revenue of $2.8 million with increased pharmacy orders, and full-year 2025 revenue of $10.2 million. Bethany Sensenig was appointed to the Board of Directors in April 2026. Analyst coverage included a "buy" recommendation from Craig-Hallum, but a downgrade to "sell" from Wall Street Zen. The stock's price has decreased by 6.89% over the last 12 months.